# Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

> **NCT02964572** · NA · COMPLETED · sponsor: **Yonsei University** · enrollment: 61 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Glimepiride
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT02964572
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964572, "Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02964572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*